Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting

Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company has presented a poster abstract on minimal residual disease ("MRD") during the 22nd International Myeloma Society Annual Meeting in Toronto, Canada.

The abstract, titled "3D Telomere Profiling of MRD in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression", was presented at the meeting by Dr. Yulia Shifrin, Laboratory Director of Telo Genomics. The abstract will be published as a special supplement to the Clinical Lymphoma, Myeloma, & Leukemia Journal and made available on the Company website.

The poster presentation describes a new workflow for MRD evaluation that combines the enumeration and immunophenotyping of individual Multiple Myeloma (MM) Circulating Tumor Cells (CTCs), with the TeloView^® 3D telomere profiling platform. The evaluation of CTCs from peripheral blood, rather than bone marrow, offers a less invasive biomarker for MM that allows for continuous monitoring of patients. Unlike conventional approaches, this approach yields functional and biologically actionable data on disease cells, providing insights on risk of disease progression beyond simple enumeration.

The International Myeloma Society (IMS) is a global professional organization dedicated to advancing the science and treatment of multiple myeloma. Its 22nd Annual Meeting is taking place from September 17-20, 2025. IMS meetings are widely considered as a defining annual forum in the myeloma field.

About Telo Genomics
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.